Person: SARANDÖL, EMRE
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SARANDÖL
First Name
EMRE
Name
6 results
Search Results
Now showing 1 - 6 of 6
Publication Evaluation of percentage recovery together with modified reference range in hyperprolactinemia(Walter De Gruyter Gmbh, 2020-02-01) Dirican, Melahat; Açıkgöz, Hacer Ebru; Sarandöl, Emre; SARANDÖL, EMRE; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; AAG-6985-2021; ABE-1716-2020Objective: Macroprolactinemia is an important cause of hyperprolactinemia. The aim of this study was to examine the added value of the consideration of modified reference range in determination of macroprolactinemia and true hyperprolactinemia.Materials and methods: Three hundred and ninety patients with high and 131 with normal prolactin (PRL) levels were included in this study. PRL had been analyzed before and after polyethylene glycol precipitation (postPEG PRL). Recovery percentage (R%) <40% and >60% had been reported as macroprolactinemia and true hyperprolactinemia, respectively. Post-PEG PRL levels were evaluated according to the modified reference range obtained from those of the normoprolactinemic subjects.Results: According to the R% criterion; macroprolactinemia had been detected in 24.9% and true hyperprolactinemia in 67.4% of hyperprolactinemic patients. When the data were evaluated considering the post-PEG PRL levels according to the modified reference range; 13 (13.4%) of the 97 macroprolactinemia reports would be considered as true hyperprolactinemia and 6 (2.3%) of the 263 true hyperprolactinemia reports would be changed as macroprolactinemia.Conclusion: Discrimination capacity of R% criterion for true hyperprolactinemia and macroprolactinemia is limited, and we suggest that, in accordance with R% criterion, laboratory reports should include the post-PEG PRL levels along with the modified reference range.Publication Which frequency is better for pediatric shock wave lithotripsy? Intermediate or low: A prospective randomized study(Springer, 2021-04-22) Kaygısız, Onur; Çiçek, Mehmet Çağatay; Mert, Ahmet; Akesen, Selcan; Sarandöl, Emre; Kılıçarslan, Hakan; KAYGISIZ, ONUR; ÇİÇEK, MEHMET ÇAĞATAY; AKESEN, SELCAN; SARANDÖL, EMRE; KILIÇARSLAN, HAKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Anesteziyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; 0000-0002-9790-7295; 0000-0002-0471-5404; 0000-0003-4236-3646; 0000-0002-2593-7196; L-9439-2019; HGM-5995-2022; ELR-9087-2022; DXM-3644-2022; FGY-3115-2022Purpose Shock wave lithotripsy (SWL) is the first option in the treatment of pediatric kidney stones; however, optimal frequency is still uncertain. The aim of this study was to compare low frequency [60 shocks per minute (SWs/min)] and intermediate frequency [90 SWs/min] in terms of lithotripsy success, complications, cardiac arrhythmia, anesthesia time, secondary procedures, and efficiency quotient (EQ) in children. Methods Seventy-eight consecutive children who received SWL for radiopaque renal stones between July 2016 and January 2020 were randomly divided into two groups: Group 60 (SWL frequency: 60 SWs/min) and Group 90 (SWL frequency: 90 SWs/min). After exclusion (remaining 71 children), Group 60 (n = 38) and Group 90 (n = 33) were compared using univariate analysis. Results The median age of children (37 girls, 34 boys) was 5 (1-16) years. Patient demographics and stone features were similar between the groups. Success rate after the last SWL session was 81.6% (n = 31) for Group 60 and 87.9% (n = 29) for Group 90 (p = 0.527). Stone-free rate after the first, second, and third sessions was 42.1%, 18.4%, and 21.1% for Group 60 and 48.5%, 27.3%, and 12.1% for Group 90, respectively. Additional treatment rate was similar between the groups. In Group 60, the EQ was 57.83, and it was 64.07 in Group 90. Median total anesthesia time was significantly longer in Group 60 (74.5 min) than in Group 90 (32 min; p < 0.001). Conclusion Intermediate frequency and low-frequency pediatric SWL have similar success rates; however, intermediate-frequency SWL has a shorter anesthesia time.Publication The effect of different antihypertensive treatment protocoles on oxidant-antioxidant systems in type 2 diabetic patients with microalbuminuria and stage 1 hypertension(Oxford Univ Press, 2015-05-01) Ersoy, Alparslan; Erek, Müge; Ersoy, Canan; Sarandöl, Emre; Yıldız, Abdülmecit; ERSOY, ALPARSLAN; Erek, Müge; ERSOY, CANAN; SARANDÖL, EMRE; YILDIZ, ABDULMECİT; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; AAH-5054-2021; ABE-1716-2020; AAH-8861-2021; EWD-8165-2022; HIG-9032-2022Publication Effect of rosiglitazone and insulin combination therapy on inflammation parameters and adipocytokine levels in patients with Type 1 DM(Hindawi, 2015-03-17) Güçlü, Metin; Gül, Özen Öz; Cander, Soner; Ünal, Oğuzkaan; Özkaya, Güven; Sarandöl, Emre; Ersoy, Canan; Güçlü, Metin; ÖZ GÜL, ÖZEN; CANDER, SONER; Ünal, Oğuzkaan; ÖZKAYA, GÜVEN; SARANDÖL, EMRE; ERSOY, CANAN; Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; 0000-0001-5082-9894; 0000-0003-0297-846X; A-4421-2016; ABE-1716-2020; AAI-1005-2021; ABI-4847-2020; AAH-8861-2021; HUR-0563-2023; IPU-7626-2023Aim. To investigate the efficacy of combined therapy of insulin and rosiglitazone on metabolic and inflammatory parameters, insulin sensitivity, and adipocytokine levels in patients with type 1 diabetes mellitus (type 1 DM). Material and Methods. A total of 61 adults with type 1 DM were randomly and prospectively assigned in open-label fashion to take insulin and rosiglitazone 4mg/day (n - 30) or insulin alone (n = 31) for a period of 18 weeks while undergoing insulin therapy without acute metabolic complications. Results. Combination therapy did not significantly improve metabolic and inflammatory parameters, insulin sensitivity, and adiponectin levels. While leptin and resistin levels decreased in both groups (group 1: resistin 6.96 +/- 3.06 to 4.99 +/- 2.64, P = 0.006; leptin 25.8 +/- 17.6 to 20.1 +/- 12.55, P = 0.006; group 2: resistin 7.16 +/- 2.30 to 5.57 +/- 2.48, P = 0.031; leptin 16.72 +/- 16.1 to 14.0 +/- 13.4, P = 0.007) Hgb and fibrinogen levels decreased only in group 1 (Hgb 13.72 +/- 1.98 to 13.16 +/- 1.98, P = 0.015, and fibrinogen 4.00 +/- 1.08 to 3.46 +/- 0.90, P = 0.002). Patients in both groups showed weight gain and the incidence of hypoglycemia was not lower. Discussion. The diverse favorable effects of TZDs were not fully experienced in patients with type 1 DM. These results are suggesting that insulin sensitizing and anti-inflammatory characteristics of TZDs were likely to be more pronounced in patients who were not totally devoid of endogenous insulin secretion.Publication Serum fetuin-a levels for the detection and evaluation of the left ventricular systolic heart failure(Elsevier, 2013-10-29) Keçebaş, Mesut; Güllülü, Sümeyye; Sağ, Saim; Açıkgöz, Ebru; Besli, Feyzullah; Şentürk, Tunay; Kaderli, Aysel Aydın; Özdemir, Bülent; Baran, İbrahim; Sarandöl, Emre; Aydınlar, Ali; Keçebaş, Mesut; GÜLLÜLÜ, NAZMİYE SÜMEYYE; Sağ, Saim; Açıkgöz, Ebru; Besli, Feyzullah; ŞENTÜRK, TUNAY; Kaderli, Aysel Aydın; ÖZDEMİR, BÜLENT; Baran, İbrahim; SARANDÖL, EMRE; AYDINLAR, ALİ; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı; 0000-0002-6206-8700; C-1517-2017; ABE-1716-2020; AAW-9185-2020; AAI-6632-2021; JKQ-3658-2023; JGR-6552-2023; CBS-6076-2022; DXE-4816-2022; CXL-7581-2022; JHE-3353-2023; CDA-1396-2022Publication The effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease(Springer London Ltd, 2022-01-23) Ermurat, Selime; Güllülü, Mustafa; Sarandöl, Emre; GÜLLÜLÜ, MUSTAFA; SARANDÖL, EMRE; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Klinik Biyokimya Anabilim Dalı.; JGS-9425-2023; DXM-3644-2022Background Among one of the common hereditary causes of chronic kidney disease is autosomal-dominant polycystic kidney disease (ADPKD), and its incidence rate is reported as one between 500 and 1.000 individuals. The most common complications of ADPKD are hypertension (HT) and end-stage renal disease (ESRD). HT occurring in the early stage of ADPKD leads to deteriorations in renal function. Aims It was aimed to investigate the ischemia-modified albumin (IMA) levels and the effect of renin-angiotensin-aldosterone system (RAAS) blockers on serum IMA levels in patients with ADPKD. Methods One hundred and fifteen patients were included as ADPKD (n = 50), HT (n = 35), and healthy control (HC) groups (n = 30). Patients with ADPKD and HT were divided into two subgroups as RAAS blocker-users and non-users. Results Serum IMA levels were detected as 0.42 (0.17-0.80) in ADPKD and 0.28 (0.04-0.51) in HT and 0.36 (0.22-0.56) in HC groups as absorbance units (ABSU), and the highest serum IMA level was seen in Group ADPKD. Serum IMA levels were 0.33 +/- 0.14 in RAAS blocker-users and 0.41 +/- 0.11 ABSU in non-users with ADPKD. Serum IMA levels were witnessed to be significantly lower in RAAS blocker-users in Groups ADPKD (p = 0.038) and HT (p = 0.004), compared to non-users. Given basal and 6-month values of those with ADPKD, the levels of serum IMA within 6 months were significantly lower (p = 0.002). Conclusions We consider that serum IM levels should be assessed in oxidative stress (OS)-related conditions, such as ADPKD, and RAAS blockers may be effective in reducing serum IMA levels in ADPKD and HT patients.